Heart Failure Cases Split Evenly Between Reduced, Preserved Ejection Fraction
The prevalence of heart failure is increasing as the demographic profile of the American population gets older.
The prevalence of heart failure is increasing as the demographic profile of the American population gets older.
An estimated 6.2 million American adults, age 20 and older, had heart failure between 2013 and 2016, compared with an estimated 5.7 million between 2009 and 2012.
Of incident hospitalized heart failure events, approximately half are characterized by reduced ejection fraction and half by preserved ejection fraction.
The prevalence of heart failure with preserved ejection fraction, compared with prevalence of heart failure with reduced ejection fraction, appears to be increasing along with aging of the population.
FDA Issues Complete Response Letter for Onpattro in Heart Failure Indication
October 9th 2023Alnylam Pharmaceuticals will no longer pursue this indication of Onpattro and will instead on focus on a label expansion for Amvuttra, which is in phase 3 development to treat patients with cardiomyopathy of ATTR amyloidosis.
Read More
FDA Advisory Committee Backs Use of Onpattro in Heart Failure Indication
September 16th 2023Even though committee members voted in support of Onpattro for patients with cardiomyopathy related to transthyretin-mediated amyloidosis, there were questions about whether it provided a clinically meaningful benefit. The FDA set an action date of Oct. 8, 2023.
Read More
